Behavioral side-effects of levetiracetam in children with epilepsy: A systematic review  by Halma, Elisabeth et al.
Seizure 23 (2014) 685–691Review
Behavioral side-effects of levetiracetam in children with epilepsy:
A systematic review
Elisabeth Halma a, Anton J.A. de Louwa,*, Sylvia Klinkenberg b, Albert P. Aldenkamp c,d,e,
Dominique M. IJff c, Marian Majoie a
aDepartment of Neurology, Epilepsy Centre Kempenhaeghe, Heeze, The Netherlands
bDepartment of Neurology, Maastricht University Medical Centre, Maastricht, The Netherlands
cDepartment of Behavioral Research and Clinical Neuropsychology, Epilepsy Centre Kempenhaeghe, Heeze, The Netherlands
d Faculty of Electrical Engineering, University of Technology, Eindhoven, The Netherlands
eDepartment of Neurology, University Hospital Gent, Gent, Belgium
A R T I C L E I N F O
Article history:
Received 7 April 2014
Received in revised form 24 May 2014
Accepted 4 June 2014
Keywords:
Anti-epileptic drugs
Levetiracetam
Epilepsy
Children
Behavioral problems
Behavior
A B S T R A C T
Purpose: Children with epilepsy are more likely to have behavioral problems compared to children
without epilepsy. Literature suggests that levetiracetam leads to behavioral side-effects in children with
epilepsy. The objective of this study is to provide a better overview of the frequency and variety of
behavioral side-effects, which can be initiated by levetiracetam therapy in children with epilepsy.
Method: Electronic databases used in the search were PubMed, Medline, Cochrane and Embase. Studies
were eligible for inclusion when they included children from one month to 18 years of age with a
diagnosis of epilepsy, used levetiracetam, had other AEDs on a stable regimen for at least two months,
reported about behavioral side-effects and had a follow-up of at least two weeks. Quality assessments
and data collection were carried out for all eligible studies.
Results: Thirteen studies, including 727 patients using levetiracetam, were included in this systematic
review. Three randomized controlled trials showed a total of 62 behavioral side-effects in 203 patients,
effects which led to discontinuation of levetiracetam in only two of 102 patients (2.0%). Hostility,
nervousness and aggression were reported mostly. Meta-analysis showed a statistically signiﬁcant
relative risk of 2.18 for the total number of behavioral side-effects for levetiracetam versus placebo.
Observational studies showed mixed results with both behavioral deteriorations and improvements
following levetiracetam.
Conclusion: Based on the ﬁndings in this systematic review, children using levetiracetam have a risk of
developing several behavioral side-effects such as aggression, hostility and nervousness compared to
children who do not use levetiracetam.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy is a common neurological disorder with a peak
incidence in childhood affecting four to ten children per 1000.1,2
Childhood-onset epilepsy is associated with mental retardation,
developmental disabilities, behavioral problems and psychosocial
problems in the long term.1,3 Psychiatric comorbidity such as
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in children with epilepsy compared to children without epilepsy.2
Despite the fact that various antiepileptic drugs are known to
initiate or worsen already existing behavioral problems, they are
still the mainstay of treatment in children with epilepsy.3
Behavioral problems, ranging from mild to severe, may be exerted
by any anti-epileptic drug (AED). Other factors, such as patients’
characteristics and poly- or monotherapy with AEDs, also have an
inﬂuence on the expression and severity of these behavioral
problems.3,4 Polytherapy with AEDs may lead to a higher risk
of developing side-effects, including behavioral side-effects,
compared to monotherapy.3
Levetiracetam is a second-generation antiepileptic drug that
has been approved for the treatment of epilepsy in both children
and adults. This anticonvulsant drug has a unique mechanismserved.
E. Halma et al. / Seizure 23 (2014) 685–691686which involves binding to the synaptic vesicle protein 2A resulting
in a possible effect on neurotransmitter release from these
presynaptic vesicles, although the exact mechanism of action is
still unknown.5,6 In children, the recommended dose for levetir-
acetam is 10–60 mg/kg/day compared to 1000–3000 mg/day in
adults. The pharmacokinetics in children differs only slightly from
in adults, characterized by a faster elimination rate.7,8 The daily
maintenance dose of levetiracetam children should be 130–140%
of the daily dose used in adults due to the 30–40% higher plasma
clearance. But this dose should be corrected for body weight and
given in divided doses in children.7
Levetiracetam treatment in adults has a proven efﬁcacy in both
localization-related and generalized epilepsies.9–19 This is also
proven in children with localization-related and generalized
epilepsies.20–29 Behavioral side-effects of levetiracetam have been
frequently reported and consist of a variety of behavioral
problems, including aggression as well as changed mood states
such as depression, agitation, hostility, irritability and hyperexcit-
ability.30 Commonly the reported behavioral side-effects are of an
activating-type; ‘uppers’ as described by Ketter et al. and Roberts
et al.31,32 Such effects may lead to early discontinuation of
levetiracetam resulting in an inadequate seizure control.33
However, only a few studies systematically report the behavioral
side-effects of levetiracetam in children.
The objective of this study is to provide a better overview of the
frequency and variety of behavioral side-effects of levetiracetam
therapy in children with epilepsy. We will, therefore, review the
existing literature systematically.
2. Methods
2.1. Search strategy
In October 2013 and March 2014 a search was conducted in
PubMed, Medline, Cochrane and Embase. Subsequently the refer-
ence lists of relevant articles were reviewed to search for additional
relevant studies. The major search terms included children, epilepsy,
levetiracetam and behavior. A complete overview of the search402 articles identified 
through database searchin g
57 additional a
identified in refer
394 articles after discarding duplicates 
andtitlebyscreenedAll abstract
34 full-text articles assessed for 
eligibility
13 articles included in qualitative 
synthesis
Fig. 1. Flow-diagram of study idstrategy in PubMed is provided in the Appendix A. When possible a
couple of limits were used concerning language (English, Dutch or
German), age (one month–18 years), journal articles and original
trials.
2.2. Selection criteria
Studies were eligible for inclusion when they met the following
criteria: children from one month to 18 years of age, diagnosis of
epilepsy, using levetiracetam mono- or add-on therapy, follow-up
of at least two weeks and reporting about behavioral side-effects.
Exclusion criteria were: studies concerning children and adults
without subgroup analyses for children, case reports (<10
patients), studies written in a language other than English, Dutch
or German, studies reporting neonatal convulsions or intravenous
therapy with levetiracetam. The search and selection of eligible
studies were carried out by three authors (EH, AL, MM).
2.3. Review methods
Quality assessments and data collection were performed for all
eligible studies using a standardized form taking the risk of bias
into account. Data collection included study design, demographic
information on patients including type of epilepsy, blinding,
randomization, dose of levetiracetam, duration of treatment and
follow-up and number of reported behavioral side-effects. When
behavioral side-effects were reported we analyzed behavioral
problems in general including aggression and changed mood states
such as hostility, agitation, irritability, hyperactivity, nervousness,
restlessness, emotional lability, impulsiveness as well as psychi-
atric effects such as anxiety states, depression, dysphoria or
psychosis.
2.4. Data analysis
The numbers of behavioral side-effects reported in patients
from the included studies were counted. Subsequently we deﬁned
subgroups to look at the number of behavioral side-effects inrticles 
ence lists
360 articles excluded 
Reasons: did not meet inclusion 
criteria 
21 full-text articles excluded 
Reasons: 
• 4 had a non-stable 
regimen of other AEDs 
• 14 did not report regimen 
of other AED’s 
• 1 had follow-up of 5 days 
and 111/116 entered long-
term follow-up study 
• 1 did not report 
behavioural side effects 
• 1 observational study used 
the same population as a 
previous RCT  
entiﬁcation and selection.
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used to perform a Chi-square or Fisher’s exact test to compare the
number of (speciﬁc) behavioral side-effects between patients
using levetiracetam and patients using placebo, p < 0.05 indicating
statistical signiﬁcance. A meta-analysis for total number of
behavioral side-effects was performed using Review Manager 5
software. Statistical heterogeneity was assessed by describing I2.
Values of 25% were considered as low heterogeneity, 50% as
moderate heterogeneity and 75% as high heterogeneity.34
3. Results
3.1. Study selection
The ﬂow diagram in Fig. 1 describes the process of study
selection. Database searching and reviewing the reference lists
identiﬁed 394 articles after duplicates were removed. Of these 360Table 1
Study characteristics of included studies.
Study Study design LEV therapy Diagnosisa
Lagae (2003)36
(n = 21)
Prospective,
open-label
Add-on Localization-rela
epilepsies and g
epilepsies
Nakken (2003)37
(n = 44)
Prospective,
open-label
Add-on Localization-rela
epilepsies and g
epilepsies
Aeby (2005)38
(n = 12)
Retrospective Add-on (n = 11)
and mono (n = 1)
Epilepsies and s
undetermined w
or generalized: 
generalized and 
Lagae (2005)29
(n = 77)
Prospective,
open-label
Add-on (n = 67)
and mono (n = 10)
Localization-rela
epilepsies and g
epilepsies
Glauser (2006)27
(n = 198)
Randomized,
double-blind,
placebo-
controlled
Add-on Localization-rela
epilepsies
Khurana (2007)39
(n = 18)
Retrospective Mono Localization-rela
epilepsies and g
epilepsies
Perry (2008)40
(n = 86)
Retrospective,
LEV (n = 66) vs.
CBZ (n = 20)
Mono Localization-rela
epilepsies
Verrotti (2008)41
(n = 21)
Prospective,
open-label
Mono Generalized epil
Levisohn (2009)26
(n = 98)
Randomized,
double-blind,
placebo-
controlled
Add-on Localization-rela
epilepsies
Pina-Garza (2010)42
(n = 152)
Prospective,
open-label
Add-on Localization-rela
epilepsies
Chhun (2011)43
(n = 102)
Prospective,
open-label
Add-on Localization-rela
epilepsies, gener
epilepsies and e
syndromes unde
whether focal or
with both gener
focal seizures
Fattore (2011)28
(n = 59)
Randomized,
double-blind,
placebo-
controlled
Mono Generalized epil
Kanemura (2013)44
(n = 11)
Case series Add-on Localization-rela
epilepsies and e
syndromes unde
whether focal or
with both gener
focal seizures
n, number of patients included in study; LEV, levetiracetam; CBZ, carbamazepine.
a Classiﬁcation of epilepsies and syndromes according to ILAE 1989.did not meet inclusion criteria leaving 34 articles to be fully
assessed by using the entire text. Studies were excluded when it
was not clear if the other AEDs were on a stable regimen during the
study period with levetiracetam. Schiemann-Delgado et al.35
performed a long-term open-label extension study which includes
a large part (80/98) of the study population used by Levisohn
et al.26 We, therefore, decided to exclude this study and not to use
the reported side-effects.35 Eventually a total of thirteen articles
met the eligibility criteria and were included in the review. The
study characteristics are shown in Table 1.
3.2. Risk of bias in included studies
Only three studies were randomized, placebo-controlled and
double-blind leading to a low risk of selection and information
bias.26–28 However, two out of three did not describe who were
blinded to the intervention.26,28 In nine studies all participantsAges Dosage
(mg/kg/d)
(mean)
Follow-up
(mean)
Behavioral
side-effect
ted
eneralized
6 mo–14 yr 17–60 (37) 12 wk Spontaneously
reported
ted
eneralized
3–17 yr 10–40 3–14 mo
(8 mo)
Spontaneously
reported
yndromes
hether focal
with both
focal seizures
4–14 yr 50 2 mo Spontaneously
reported
ted
eneralized
6 mo–16 yr 12–62
(mono: 29,
add-on: 33)
20 wk Structured
questionnaire
ted 4–16 yr 40–60 14 wk Spontaneously
reported
ted
eneralized
2.5–18 yr 14–60 (25) 2–24 mo Spontaneously
reported
ted <16 yr Unknown 6 mo Spontaneously
reported
epsies 5–13 yr 31–70 6 mo Structured
questionnaire
ted 4–16 yr 20–60
(53.6)
12 wk Spontaneously
reported
ted 1 mo–<4 yr 10.5–95.4
(56.1)
30–42 wk
(41 wk)
Spontaneously
reported,
structured
questionnaire
ted
alized
pilepsies and
termined
 generalized:
alized and
6 mo–15 yr 25.0–44.8
(31.1)
6 mo Structured
questionnaire
epsies 4–16 yr 10–30
(28.5)
14 dy Spontaneously
reported
ted
pilepsies and
termined
 generalized:
alized and
4.7–11.3 yr 19.4–57.7
(44.8)
6 mo Spontaneously
reported
Fig. 2. Quality assessment of included studies.
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blinding were not applicable to these studies resulting in a high
risk of information bias.29,36–39,41–44 The risk of selection bias was
low in these studies since the inclusion and exclusion criteria were
well-chosen and clearly described in seven out of nine stud-
ies.29,36,37,39,41–43 One study retrospectively compared levetirace-
tam and carbamazepine, but only the results of levetiracetam
treatment were described here.40 About half of studies (6/13) used
an intention to treat analysis26–28,36,42,43 and all provided a
complete description of withdrawals.26–29,36–44 Only one study
had a follow-up duration of less than two months (fourteen
days).28
In conclusion, there is a large heterogeneity among the included
studies with regard to study design, study population, intervention
and outcome measures (Fig. 2). Ten studies did not include a
control group and therefore a meta-analysis was not possible.29,36–
44 The randomized controlled trials were not sufﬁciently homoge-
neous concerning speciﬁc behavioral side-effects. Therefore, we
could only carry out a meta-analysis for the total number of
behavioral side-effects from these studies.26–28 Because of the
heterogeneity among the included studies and differences in levels
of evidence, the results of the randomized controlled trials and the
results of the observational studies will be described separately.
3.3. Evidence from randomized controlled trials
Three randomized controlled trials were included in
this study.26–28 A total of 62 behavioral side-effects were
reported in 203 patients with hostility (5.9%), nervousnessTable 2
Statistical tests of behavioral side-effects between levetiracetam and placebo.
Study Outcome measure Leve
Levisohn (2009) Aggression 8/64
Abnormal behavior 5/64
Hyperactivity 4/64
Anxiety 4/64
Altered mood 4/64
Total no. of behavioral side-effects 25/6
Glauser (2006) Hostility 12/1
Nervousness 10/1
Emotional lability 6/10
Agitation 6/10
Total no. of behavioral side-effects 34/1
Fattore (2011) Irritability 2/38
Dysphoria 1/38
Total no. of behavioral side-effects 3/38(4.9%) and aggression (3.9%) being reported mostly. One-
hundred and sixty-ﬁve patients received levetiracetam add-on
therapy and 59 behavioral side-effects were reported within
this group (mostly hostility (7.3%), nervousness (6.1%) and
aggression (4.9%)).26,27
There is a statistically signiﬁcant difference in the total
number of behavioral side-effects between patients receiving
levetiracetam and patients receiving placebo in the study of
Glauser et al.27 but this was not found in the study by Levisohn
et al.26 and Fattore et al.28 No statistically signiﬁcant differences
were found between levetiracetam and placebo for speciﬁc
behavioral side-effects with the exception of nervousness
(Table 2). Overall, 62 behavioral side-effects in 203 patients
using levetiracetam compared to 21 behavioral side-effects
in 152 patients using placebo does show a trend of behavioral
side-effects being more prevalent in patients using levetirace-
tam over placebo.
Fig. 3 shows the meta-analysis on total number of behavioral
side-effects of levetiracetam versus placebo. This shows a
statistically signiﬁcant risk ratio of 2.18 [1.42, 3.37] for
behavioral side-effects when using levetiracetam compared to
placebo.
Two randomized controlled trials reported speciﬁc reasons for
discontinuation of levetiracetam.26,28 In these 102 patients, only
two patients (2.0%) stopped using levetiracetam because of
behavioral side-effects (abnormal behavior/depression and agita-
tion). In the study of Glauser et al. ﬁve of 101 patients discontinued
levetiracetam because of side-effects but they did not clarify if
behavioral side-effects were involved.27tiracetam Placebo p value (test used)
 3/34 p = 0.743 (2-sided Fisher’s exact)
 0/34 p = 0.160 (2-sided Fisher’s exact)
 5/34 p = 0.269 (2-sided Fisher’s exact)
 0/34 p = 0.295 (2-sided Fisher’s exact)
 0/34 p = 0.295 (2-sided Fisher’s exact)
4 8/34 p = 0.121 (Chi-square)
01 6/97 p = 0.163 (Chi-square)
01 2/97 p = 0.033 (2-sided Fisher’s exact)
1 4/97 p = 0.748 (2-sided Fisher’s exact)
1 1/97 p = 0.119 (2-sided Fisher’s exact)
01 13/97 p = 0.001 (Chi-square)
 0/21 p = 0.534 (2-sided Fisher’s exact)
 0/21 p = 1.000 (2-sided Fisher’s exact)
 0/21 p = 0.546 (2-sided Fisher’s exact)
Fig. 3. Forest plot of total number of behavioral side-effects, levetiracetam versus placebo.
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A total number of 89 behavioral side-effects were reported in
524 patients. Not all studies reported speciﬁc behavioral side-
effects; ﬁve studies reported behavioral side-effects in general.36–
40 Overall the most reported behavioral side-effects were
behavioral problems in general (5.0%), irritability (4.2%), and
hyperexcitability (3.4%). Additional behavioral side-effects which
were reported were aggression (2.1%), agitation (1.2%), restless-
ness (1.0%) and psychosis (0.2%).
Seven studies, including 408 patients, used levetiracetam
add-on therapy in localization-related or generalized epilepsies
and reported a number of 64 behavioral side-effects.29,36–38,42–44
Irritability (4.7%), hyperexcitability (4.4%) and aggression (2.7%)
were reported mostly within this group. Monotherapy was given
in 116 patients with localization-related or generalized epilep-
sies.29,38–41 In this subgroup a total of 25 behavioral side-effects,
consisting of behavioral problems in general (19.0%) and
irritability (2.6%), were found.
Nine studies, including 422 patients, reported speciﬁc reasons
for discontinuation of levetiracetam.29,36–42,44 Behavioral side-
effects were a reason for discontinuation in eleven patients
(2.6%). In one other study, ﬁve of 102 patients discontinued
levetiracetam because of side-effects but they did not specify the
different side-effects.43
Three studies also reported possible improvements in behavior
after starting levetiracetam. In seven of eleven patients, hyperac-
tivity and impulsivity improved after levetiracetam treatment;
these patients were all responders.44 In the second study,
seventeen of 77 patients showed better behavior, meaning it
became easier to handle the children and introduce more structure
in their behavior.29 In the last study, seven of twelve patients
showed improved behavior after two months of levetiracetam as
reported by the parents and/or school; all these patients also
showed an improvement on their electroencephalogram.38
4. Discussion
The objective of this systematic review was to provide a better
overview of the frequency and variety of behavioral side-effects of
levetiracetam in children with epilepsy. We conducted a literature
review of various behavioral side-effects most likely to be initiated
by levetiracetam in children.
Most reported ﬁndings from randomized controlled trials were
hostility, nervousness and aggression. We showed that behavioral
side-effects are indeed frequently reported when using levetir-
acetam with a total number of 62 behavioral side-effects occurring
in 203 patients. A statistically signiﬁcant difference in the total
number of behavioral side-effects between patients receiving
levetiracetam versus placebo was found in only one randomized
controlled trial. Also Chi-square and Fisher’s exact tests showed
no statistical signiﬁcance for speciﬁc behavioral side-effects
except for nervousness. A possible explanation might be the low
number of patients included in the analyses for speciﬁc behavioralside-effects. However, the meta-analysis did show a statistically
signiﬁcant risk ratio of 2.18 for levetiracetam versus placebo. These
behavioral side-effects led to discontinuation of levetiracetam in
only two of 102 patients (2.0%). This might be an underestimation
since one other study reported discontinuation of levetiracetam
due to side-effects in ﬁve patients which possibly include
behavioral side-effects. On the other hand, Bertsche et al. analyzed
therapy failure of levetiracetam and other AEDs and they also
reported a low number of patients discontinuing levetiracetam
because of side-effects; the majority of patients stopped levetir-
acetam because of lack of effectiveness.45
The evidence from the observational studies showed mixed
results with both behavioral deteriorations and improvements
following levetiracetam. Epilepsy in children is associated with
behavioral problems and a negative psychosocial impact.1,3
Improvements in behavior by levetiracetam may, therefore, be
related to a better seizure control.2 Behavioral improvements in
the long-term may be explained by parents getting used to their
child’s behavior or because the dose of levetiracetam was ﬂexible
during a long-term, open label study.42 It would have been
interesting to look at the timing of and inﬂuence of the dose on
behavioral side-effects. Unfortunately only one observational
study reported on the timing of behavioral side-effects and
another about the inﬂuence of the dose of levetiracetam. Due to
this lack of evidence we decided not to include these topics in our
systematic review.
It is worth speculating about the clinically relevance of
behavioral side-effects caused by levetiracetam since a very low
number of patients discontinued levetiracetam in both random-
ized controlled trials and observational studies. This low number
indicates that the behavioral side-effects are not that severe
because otherwise probably more patients would have discon-
tinued levetiracetam. Also Bootsma et al. assume that side-effects
are only clinically meaningful when an AED is discontinued
because of this side-effect.46
The reported behavioral side-effects in the included studies are
all of an activating-type; deﬁned as ‘uppers’ by Ketter et al.31 This is
not in line with previous studies of Roberts et al. and Bootsma et al.
who found both activating and deactivating side-effects in patients
using levetiracetam.32,46 Both children and adults who used
levetiracetam were included in these studies; it might be possible
that adults are more likely to develop deactivating side-effects
compared to children.
Unfortunately, most studies (10/13) were neither randomized
nor blinded and, therefore, are inﬂuenced by varying methodology,
information bias and the validity of measuring behavioral side-
effects since in most studies behavioral side-effects had to be
reported spontaneously or were asked about by the investigator.
This method is vulnerable to bias because parents are probably
familiar with the possible side-effects of the medication and more
likely to answer ‘yes’ to a speciﬁc question asked by the doctor. This
may result in a possible overestimation of behavioral side-effects.
The lack of randomized controlled trials concerning behavioral
side-effects of levetiracetam in children may be explained by
E. Halma et al. / Seizure 23 (2014) 685–691690ethical objections, as it is not ethically justiﬁed to give children
medication in order to look for harmful side-effects.
As far as we know, this is the ﬁrst systematic review on
behavioral side-effects of levetiracetam in children with epilepsy.
We have demonstrated a noteworthy frequency and variety of
behavioral side-effects in children using levetiracetam but the
severity of these behavioral side-effects is still a point of
discussion. However, our results suggest that behavioral problems
are more likely to occur or worsen in patients using levetiracetam
compared to patients using placebo. Further research is needed to
gain a better understanding of the relation between seizure control
and deterioration or improvement in behavior. The severity and
impact of the behavioral side-effects caused by levetiracetam in
children should also be investigated. Based on the ﬁndings in this
systematic review, children using levetiracetam have a risk of
developing several behavioral side-effects such as aggression,
hostility and nervousness compared to children who do not use
levetiracetam.
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Appendix A. Search strategy PubMed
1. (infant[Mesh] OR infant OR infants) OR (baby OR babies) OR
(neonate OR neonates OR neonatal) OR (perinate OR perinates
OR perinatal) OR (postnatal OR postnates) OR (child[Mesh] OR
child OR children) OR (schoolchild OR schoolchildren) OR (kid
OR kids) OR (toddler OR toddlers) OR (adolescent[Mesh] OR
adolescent OR adolescents OR teen OR teens) OR (boy OR boys
OR girl OR girls) OR (minors OR underage OR underaged OR
‘‘under aged’’) OR (juvenile OR juveniles OR youth) OR
(puberty[Mesh] OR puberty OR puber OR puberal OR prepuber-
ty) OR (pediatrics[Mesh] OR pediatrics OR pediatric OR
pediatrical OR paediatric OR paediatrics OR paediatrical) OR
(schools[Mesh] OR schools OR school OR ‘‘nursery school’’
OR ‘‘nursery schools’’) OR (preschool OR ‘‘pre school’’ OR ‘‘pre
schools’’ OR ‘‘primary school’’ OR ‘‘primary schools’’) OR
(‘‘secondary school’’ OR ‘‘secondary schools’’) OR (‘‘elementary
school’’ OR ‘‘elementary schools’’) OR (‘‘high school’’ OR ‘‘high
schools’’ OR highschool OR highschools) OR (‘‘school age’’ OR
‘‘school ages’’)
2. (etiracetam[Supplementary Concept] OR Levetiracetam OR
Keppra OR Etiracetam)
3. (epilepsy[MeSH] OR epilepsy OR epileps* OR epilept*) OR
(seizures[MeSH] OR seizures OR seizure) OR (convulsion OR
convulsions)
4. ‘‘behavior’’[MeSH Terms] OR ‘‘behavior*’’ OR ‘‘behavior*’’ OR
‘‘Mood Disorders’’[Mesh] OR ‘‘Mood disorder’’ OR ‘‘Mood
disorders’’ OR ‘‘Affective disorder’’ OR ‘‘Affective disorders’’
OR ‘‘aggression’’ OR ‘‘Aggression’’[Mesh] OR ‘‘agression’’ OR
‘‘agressive’’ OR ‘‘irritability’’ OR ‘‘Irritable Mood’’[Mesh] OR
‘‘irritable’’ OR ‘‘Psychomotor Agitation’’[Mesh] OR ‘‘Agitation’’
OR ‘‘Agitated’’ OR ‘‘Agitate’’ OR ‘‘Hyperactivity’’ OR ‘‘Hyperac-
tive’’ OR ‘‘Restlessness’’ OR ‘‘Restless’’ OR ‘‘Impulsive Beha-
vior’’[Mesh] OR ‘‘Impulsive’’ OR ‘‘Impulsiveness’’ OR
‘‘Hostility’’[Mesh] OR ‘‘Hostility’’ OR ‘‘Hostile’’ OR ‘‘Nervousness’’5. Limits: Humans, Dutch, English, German, Child: birth–18 years,
Infant: birth–23 months, Adolescent: 13–18 years, Child: 6–12
years, Infant: 1–23 months, Preschool Child: 2–5 years, Journal
Article.
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